Endophilin-A1 (SH3G2) (N-Term) Peptid
SH3G2
Reaktivität: Human
Wirt: Synthetic
BP, WB
Produktnummer ABIN983694
150,78 €
Zzgl. Versandkosten 20,00 € und MwSt
100 μg
Lieferung nach:
Deutschland
Lieferung in 15 bis 22 Werktagen
Kurzübersicht für Endophilin-A1 (SH3G2) (N-Term) Peptid (ABIN983694)
Target
SH3G2
(Endophilin-A1 (SH3G2))
Spezies
Human
Quelle
Synthetic
Applikation
Blocking Peptide (BP), Western Blotting (WB)
-
-
Protein Region
- N-Term
-
Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-SH3GL2 antibody (Catalog #: ARP56549_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Aufreinigung
- Purified
-
-
-
-
Applikationshinweise
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Konzentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handhabung
- Avoid repeated freeze-thaw cycles.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- SH3G2 (Endophilin-A1 (SH3G2))
-
Hintergrund
-
SH3GL2 is implicated in synaptic vesicle endocytosis. SH3GL2 may recruit other proteins to membranes with high curvature.
Alias Symbols: CNSA2, EEN-B1, FLJ20276, FLJ25015, SH3D2A, SH3P4
Protein Interaction Partner: ADRB1,SH3KBP1,ACTG1,ADAM15,ADRB1,AMPH,ATXN2,BIN1,DNM1,EGFL6,EMD,ERH,HLA-DQA1,IL6,ITCH,MAP4K3,PAK2,PDCD6IP,SH3GL2,SH3GL3,SH3KBP1,SLC17A7,SYNJ1,TCEA2,ACTG1,ADAM15,ADAM19,ADAM9,AMPH,BIN1,CBL,DNM1,EGFL6,EMD,ERH,HLA-DQA1,IL6,SH3KBP1,SYN1,SYNJ1,SYNJ2,TCEA2
Protein Size: 352 -
Molekulargewicht
- 40 kDa
-
Gen-ID
- 6456
-
NCBI Accession
- NM_003026, NP_003017
-
UniProt
- Q99962
Target
-
Sie sind hier:
